In contrast, the multi-kinase inhibitor sorafenib activates the ERK signaling pathway, promoting TRIM54-mediated ubiquitination and the subsequent proteasomal degradation of FSP1, leading to reduced FSP1 protein levels and the induction of ferroptosis in HCC cells [26]. Here, AIFM2 is linked to hepatocellular carcinoma.